MedTrace Logo

Radiation Therapy as Palliative Treatment of GIST

NCT00515931 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-10-07

No results posted yet for this study

Summary

Gastrointestinal stromal tumors (GISTs) are generally considered resistant to radiation, but no prospective trials addressing efficacy and tolerability of radiation therapy have been carried out. Limited clinical experience suggests that selected GIST patients may benefit from palliative radiation therapy. The purpose of this prospective, non-randomized, multicenter study is to evaluate efficacy and safety of palliative radiation therapy in GIST patients who have progressive GIST during or after tyrosine kinase inhibitor therapy.

Conditions

  • Sarcoma

Interventions

RADIATION

Radiation therapy (external beam photons)

A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • University of Lausanne Hospitals

    collaborator OTHER

  • Heikki Joensuu

    lead OTHER

Principal Investigators

  • Heikki Joensuu, M.D., Ph.D. · Department of Oncology, Helsinki University Central Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2014-02-28
Completion
2014-10-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515931 on ClinicalTrials.gov